Sign in Create account

Biofil Chemicals & Pharmaceuticals Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: BIOFILCHEM BSE: 524396
₹30.38
▼ -1.14 (-3.62%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
66/100
Moderate
Valuation
37/100
Fairly Valued
Momentum
12/100
Bearish

QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹49 Cr
PE (TTM)
101.3
Industry median 36.1 (152 companies)
Price to Book
2.3
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
5
Relative return vs Nifty50, qtr %
-4.7
Relative return vs Sector, qtr %
-12.4
Free Cash Flow
₹-1 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-95.27%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-82.52%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
8.99%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-95.48%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
91.98%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.73
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.14
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
549.00
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
0.88%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
1.09%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
2.40%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
6.50%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
15.62%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
12.92%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 5)
  • Yes Debt to equity is below 0.5 (0.14)
  • No Return on equity is 15% or more (12.9%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 4 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

0 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Fair Value Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-3.6%
Low 29.6000 · High 31.8100
1W return
-5.9%
Low 29.6000 · High 32.9800
1M return
-6.8%
Low 29.6000 · High 37.8000
52W return
-26.8%
Low 25.6000 · High 46.3400
Lifetime High ₹339.1500 (Dec. 11, 2020)
Lifetime Low ₹0.9000 (Jan. 5, 1999)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
31.4
10D
32.0
20D
32.3
50D
32.6
100D
32.9
200D
33.1

Delivery and volume

Day avg. delivery
57.5%
Week avg. delivery
68.3%
Month avg. delivery
43.4%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

30.60
Pivot
First resistance31.59
Second resistance32.81
Third resistance33.80
First support29.38
Second support28.39
Third support27.17
Day RSI36.9
Day MFI69.1
Day MACD-0.29
Day MACD signal-0.03

Beta

1M1.55
3M0.89
1Y0.87
3Y1.17

Price change analysis

↓ -6.8%
Over 1 Month
LowHigh
29.6037.80
↓ -12.4%
Over 3 Months
LowHigh
29.6037.80
↑ 10.3%
Over 6 Months
LowHigh
26.9039.99
↓ -26.8%
Over 1 Year
LowHigh
25.6046.34
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 101.3 (own history: 15.1–256.1)
Fair Value Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹12 Cr
Net profit (June 30, 2026)
₹0 Cr
Basic EPS (June 30, 2026)
₹0.0700

Ranks #151 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter46.79%

Largest holders

NameCategoryShares %Shares
SCOPE FINANCE COMPANY PRIVATE LIMITEDPromoter13.9000%2262500
MID (INDIA) PHARMACEUTICALS PVT LTDPromoter7.2200%1175250
STARLINE EQUIFIN PRIVATE LIMITEDPublic7.0700%1149872
CYANO FINANCE AND SALES PVT. LTD.Promoter5.3900%876450
MEENA SHAHPromoter4.0600%660312

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 46.79% in Jun 2026 qtr

Historical fii holding

Historical mutual fund holding

All shareholding details →

Insider trading, SAST & pledges

All 9 insider trades, 16 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
20 Mar 2026 NIYATI SHAH Promoter Sell 0 ₹0
20 Mar 2026 MEENA SHAH Promoter Buy 0 ₹0
10 Jun 2025 Niyati Shah Promoter group Buy 0 ₹0
12 Mar 2024 MANALI SIMON Other Buy 0 ₹0
12 Mar 2024 SANDEEP SHAH Promoter group Sell 0 ₹0
1 Apr 2022 RAMESH SHAH Promoter Sell 0 ₹0
1 Apr 2022 Niyati Shah Immediate relative Buy 0 ₹0
7 Sep 2021 MEENA SHAH Promoter group Buy 0 ₹0
8 May 2017 RAMESH SHAH Key managerial personnel Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 161 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
27 Aug 2026 ORION STOCKS LTD Bulk Sell 89,848 32.9300 NSE
27 Aug 2026 ORION STOCKS LTD Bulk Buy 3,856 32.9400 NSE
27 Aug 2026 ORION STOCKS LTD Bulk Buy 85,992 32.9900 BSE
27 Aug 2026 ORION STOCKS LTD Bulk Sell 89,848 32.9300 NSE
27 Aug 2026 ORION STOCKS LTD Bulk Buy 3,856 32.9400 NSE
26 Aug 2026 ORION STOCKS LTD Bulk Sell 210,940 32.6300 NSE
26 Aug 2026 ORION STOCKS LTD Bulk Buy 61,787 32.4600 NSE
26 Aug 2026 IRAGE BROKING SERVICES LLP Bulk Buy 153,082 32.7600 NSE
26 Aug 2026 IRAGE BROKING SERVICES LLP Bulk Sell 19,542 32.6400 NSE
26 Aug 2026 IRAGE BROKING SERVICES LLP Bulk Buy 14,542 32.6700 BSE

All bulk and block deals →

Corporate Actions

Full history (19 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
23 Sep 2024OTHERAnnual General Meeting
20 Sep 2023OTHERAnnual General Meeting
21 Sep 2022OTHERAnnual General Meeting
17 Sep 2021OTHER Annual General Meeting
21 Sep 2020OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
11 Aug 2026 Financial Results/Other business matters Yes
30 May 2026 Financial Results/Other business matters Yes
13 Feb 2026 Financial Results Yes
13 Nov 2025 Financial Results Yes
12 Aug 2025 Financial Results Yes

Corporate Announcements

All 463 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
24 Sep 2026 Trading Window Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
24 Sep 2026 Change in Management Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about disclosure as required under sub-clause 7 of Para A of Part A of Schedule III regarding 1. Continuation of directorship of Mr. Ashok Kumar Ramawat (DIN: 08818263) as a Non-Executive Independent Director of the Company, upon attaining the age of 75 (seventy-five) years.
24 Sep 2026 Shareholders meeting Biofil Chemicals & Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 23, 2026. Further, the company has informed the Exchange regarding voting results.
23 Sep 2026 Shareholders meeting Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 23, 2026
28 Aug 2026 Copy of Newspaper Publication Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication Pursuant to Regulation 30, 44 and 47 of SEBI (LODR) Regulations, 2015 and in compliance with section 108 of the Companies Act, 2013 read with rule 20 of the Companies (Management and Administration) Rules, 2014.
26 Aug 2026 General Updates Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about about intimation of e-voting for 41st Annual General Meeting
26 Aug 2026 General Updates Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about draft letter to be dispatched to members whose email addresses not registered with the company/ depository participants
26 Aug 2026 Shareholders meeting Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2026
19 Aug 2026 Copy of Newspaper Publication Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication of Notice of 41st AGM through Video Conferencing ( VC )/ Other Audio Visual Means ( OAVM )
12 Aug 2026 Copy of Newspaper Publication Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.14)
  • Comfortable interest coverage (549.0x)
  • Healthy liquidity (Current Ratio 1.73)
  • Strong revenue growth YoY (92.0%)

Weaknesses

  • Thin net profit margin (0.9%)
  • Declining profit YoY (-95.5%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (101.3) -- priced for continued strong execution
  • Down 26.8% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Biofil Chemicals & Pharmaceuticals Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.